Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review.

ABSTRACT: Status epilepticus (SE) is a life-threatening emergency with high morbidity and mortality. In people with epilepsy, the management of SE is focused on early medical treatment. Stiripentol is a third-generation antiseizure medication (ASM) approved for refractory generalized tonic-clonic seizures in Dravet syndrome. The aim of this systematic review was to evaluate the effectiveness and safety of stiripentol in reducing the incidence of SE in patients with Dravet syndrome or any epilepsy characterized by recurrent SE. The PubMed and Cochrane databases were systematically searched, and gray literature was hand-searched. Search results were screened by title and abstract; studies with data on the effect of stiripentol on SE outcomes, including the cessation of SE, reduction in number of SE ep

SUBMITTER: Specchio N 

PROVIDER: S-EPMC11633682 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature